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Summary
Background There is a clinical concern that prescribing methylphenidate, the most common pharmacological 
treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly 
in young people with a history of psychosis. We aimed to determine whether the risk of psychotic events increases 
immediately after initiation of methylphenidate treatment or, in the longer term, 1 year after treatment initiation in 
adolescents and young adults with and without a previously diagnosed psychotic disorder.
Methods In this cohort study, we used population-based observational data from the Swedish Prescribed Drug 
Register, the National Patient Register, and the Total Population Register, three population-based registers containing 
data on all individuals in Sweden, to attain data on sex, birth, death, migration, medication use, and psychotic events 
for all eligible participants. We screened individuals on these registers to identify those receiving methylphenidate 
treatment, and who were aged 12–30 years at the start of treatment, for their inclusion in the study. We used a within-
individual design to compare the incidence of psychotic events in these individuals during the 12-week periods 
immediately before and after methylphenidate initiation. Longer term risk was assessed by comparing the incidence 
of psychotic events 12 weeks before methylphenidate initiation and during a 12-week period one calendar year before 
the initiation of methylphenidate with the incidence of these events during the 12-week period one calendar year after 
methylphenidate initiation. We estimated the incidence rate ratios (IRR) and 95% CIs of psychotic events after the 
initation of methylphenidate treatment, relative to the events before treatment, which were defined as any hospital 
visit (inpatient admission or outpatient attendance, based on data from the National Patient Register) because of 
psychosis, using the International Classification of Diseases version 10 definition. Analyses were stratified by whether 
the individual had a history of psychosis.
Findings We searched the Swedish Prescribed Drug Register to find eligible individuals who had received 
methylphenidate between Jan 1, 2007 and June 30, 2012. 61 814 individuals were screened, of whom 23 898 (38·7%) 
individuals were assessed and 37 916 (61·3%) were excluded from the study because they were outside of the age 
criteria at the start of treatment, they had immigrated, emigrated, or died during the study period, or because they 
were administered other ADHD medications. The median age at methylphenidate initiation was 17 years, and a 
history of psychosis was reported in 479 (2·0%) participants. The IRR of psychotic events in the 12-week period after 
initiation of methylphenidate treatment relative to that in the 12-week period before treatment start was 1·04 (95% CI 
0·80–1·34) in adolescents and young adults without a history of psychosis and 0·95 (0·69–1·30) among those with a 
history of psychosis. 
Interpretation Contrary to clinical concerns, we found no evidence that initiation of methylphenidate treatment 
increases the risk of psychotic events in adolescents and young adults, including in those individuals with a history of 
psychosis. Our study should reassure clinicians considering initiating methylphenidate treatment for ADHD in 
adolescents and young adults, and it challenges the widely held view in clinical practice that methylphenidate should 
be avoided, or its use restricted, in individuals with a history of psychosis. 
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Longitudinal studies1,2 have shown that attention-deficit 
hyperactivity disorder (ADHD) in childhood is a risk 
factor for a diagnosis of psychosis in adult life. Research 
indicates that these disorders share common genetic3 
and environmental aetiologies.1,4 A potential mediator of 
the association between ADHD and psychosis is 
the prescription of central stimulants for ADHD, 
which causes considerable concern for clinicians.5,6 
Clinical guidelines7 recommend stimulant medications, 
including methylphenidate and dexamphetamine, as 
first-line treatments for ADHD. Central stimulants act as 
indirect dopamine agonists and are presumed to amplify 
neuronal signalling by prompting a marked increase in 
the extracellular concentration of neurotransmitters in 
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the prefrontal cortex of the brain.8 Increased concen-
trations of synaptic dopamine have also been implicated 
in the generation of psychotic symptoms.9 Hence, the 
pharmacological mechanism of central stimulant medi-
cation can be viewed by clinicians as having the potential 
to induce psychotic symptoms and disorders.10
Data from the UK Medicines and Healthcare Products 
Agency’s Yellow Card scheme showed that, of 1335 adverse 
drug reaction reports regarding methylphenidate that had 
been received by the end of July, 2015, 663 adverse reactions 
were associated with psychiatric disorders, making these 
disorders the most frequently reported class of adverse 
drug reactions.11 Among these reports, 105 (15·8%) 
patients reported hallucinations, psychosis or psychotic 
disorders, or schizoaffective disorders. Moreover, in a 
US Food and Drug Administration review12 of data from 
49 randomised controlled clinical trials investigating the 
effects of central stimulant medication in children, 
11 adverse events related to psychosis or mania were 
observed during 743 person-years of follow-up in 
5717 individuals (1·48 events per 100 person-years, or one 
event in every 70 years of treatment), versus no events 
reported with placebo, giving a number needed to harm of 
526 patients.
Given these reports of treatment-emergent psychotic 
events with central stimulant medication, clinicians 
have been concerned that methylphenidate and other 
psychostimulants might provoke psychosis.5 Some 
clinicians even consider the use of stimulant ADHD 
medication to be contraindicated in patients with a history 
of psychosis.6 The clinical challenge of managing the 
potential risk of central stimulant treatment-emergent 
psychosis in patients with ADHD, and especially in those 
patients with history of a psychosis, has become more 
pressing with the increasing recognition, diagnosis, and 
treatment of ADHD in later adolescence and early adult 
life.7 Clinicians face a therapeutic dilemma without clear 
evidence to guide them when balancing the potential risk 
of psychotic events with the benefits of stimulants that 
are the first-line treatment for ADHD in adolescent and 
adult patients.7,13 Therapeutic uncertainty is greatest in 
patients with a history of psychosis who, theoretically, are 
assumed to be at greatest risk of stimulant treatment-
emergent psychotic events10 but who are also typically 
excluded from randomised clinical trials of ADHD 
medication.
Some observational studies6,14 that report an increased 
risk of psychotic events associated with methylphenidate 
might be affected by confounding by indication; that is, 
patients who receive stimulant medication for ADHD are 
inherently different from those who do not and could 
have a greater risk of psychotic events independently of 
stimulant prescription. In a 2016 study that adjusted for 
confounding by indication, Man and colleagues15 used 
a within-individual case series design in a population 
of children and adolescents in Hong Kong, and they 
found no increased risk of psychotic events during 
methylphenidate treatment.
Research in context
Evidence before this study
Clinical concerns have been raised that prescribing 
methylphenidate, the most common pharmacological 
treatment for attention-deficit hyperactivity disorder (ADHD), 
might increase the risk of treatment-emergent psychotic events, 
particularly in young people with a history of psychosis. 
This perceived risk can lead to clinicians withholding 
methylphenidate treatment or using less effective alternatives. 
We searched PubMed for studies published in English on or after 
Jan 1, 2000, that investigated the association between 
methylphenidate prescribing, ADHD, and psychosis. We screened 
abstracts for relevance by use of combinations of the search 
terms “methylphenidate OR stimulants”, “ADHD”, and 
“psychosis”. We also reviewed clinical guidelines from national 
bodies, including the UK National Institute of Health and Care 
Excellence and relevant Cochrane systematic reviews. There is no 
clear consensus as to whether methylphenidate treatment, 
particularly in older adolescents and young adults and in 
individuals with a history of psychosis, increases the risk of 
psychotic events. Some observational studies that report an 
increased risk of psychotic events associated with 
methylphenidate might be affected by confounding by 
indication. Clinical trial data is also relatively unhelpful in 
answering this question because of the routine exclusion of 
participants with previous psychosis, short follow-up periods, 
and the low incidence of psychotic events in these studies.
Added value of this study
We examined the risk of psychotic events in more than 
23 000 adolescents and young adults after initiation of 
methylphenidate medication by use of a within-individual 
comparison design that controls for confounding by indication. 
Contrary to clinical concerns, we did not detect an increased risk 
of psychotic events in adolescents and young adults after 
starting methylphenidate treatment. Notably, this finding also 
applies to individuals with a history of psychosis. We did not 
study other, less frequently used ADHD medications, such as 
atomoxetine and amphetamines (eg, dexamphetamine) and, 
hence, we cannot generalise our findings to these medications.
Implications of all the available evidence
Our study challenges the widely held view that 
methylphenidate should be avoided or its use restricted in 
individuals with a history of psychosis. It is important to 
confirm our findings regarding the immediate risk of psychotic 
events following methylphenidate initiation in other sample 
populations and with other study designs, which should include 
examining the effect of concomitant antipsychotic medication 
use in those with a history of psychosis.
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However, a Cochrane systematic review16,17 of ten rando- 
mised controlled trials (comprising 1103 participants) and 
17 non-randomised studies (comprising 76 237 participants) 
was unable to confirm or refute whether methylphenidate 
increases the risk of psychotic symptoms in children and 
adolescents with ADHD.
The aim of our pharmacovigilance study was twofold: 
first, we aimed to examine the risk of psychotic events 
immediately after initiation of methylphenidate treatment 
in adolescents and young adults with and without a 
previously diagnosed psychotic disorder. Second, we aimed 
to examine the longer term outcomes of methylphenidate 
exposure 1 year after treatment initiation on the risk of 
psychosis.
Methods
Study design and participants
In this population-based cohort study, we adopted a 
within-individual study design to compare the incidence 
of psychotic events within the same patients by com-
paring the incidence of events during four 12-week 
observation periods: two periods of 12 weeks, before and 
after methylphenidate initiation; the period of 12 weeks 
one calendar year before methylphenidate initiation; 
and the period of 12 weeks one calendar year after 
methylphenidate initiation (figure 1).
Our study was based in Sweden, and we used 
three population-based registers to access data from all 
eligible individuals in the country. The study population 
comprised new users of methylphenidate who were aged 
12–30 years at methylphenidate treatment initiation. New 
users were defined as individuals with a first registered 
dispensation of methylphenidate (Anatomical Therapeutic 
Chemical [ATC] code N06BA04) between Jan 1, 2007, and 
June 30, 2012, who were identified by use of the Swedish 
Prescribed Drug Register. New users included those who 
had initiated methylphenidate treatment for the first time 
and those who had not received methylphenidate for 
at least 1·5 years, since the Swedish Prescribed Drug 
Register began on July 1, 2005.  We excluded individuals 
from the study if they had received ADHD medications 
other than methylphenidate during the study period, they 
had immigrated into Sweden after the start of period 1 
(ie, one calendar year before treatment initiation), or if 
they had died or emigrated before the end of period 4 
(ie, one calendar year after treatment initiation).
The study was approved by the Regional Ethics 
Committee at Karolinska Instituet (Stockholm, Sweden). 
All data were pseudonymised before linkage and analysis, 
and individual records were completely unidentifiable 
during the analysis. Since our study was based on 
population registers, the requirement for informed 
consent was waived.
Data sources
We used the participants’ personal identification 
numbers,18 which serve as unique identifiers for all 
residents, to access patient data in three population-based 
registers in Sweden; these data include details on medi-
cation use (to enable assessment for study inclusion and of 
methylphenidate treatment) and psychotic events (to 
assess outcomes). The Swedish Prescribed Drug Register19 
contains data on all drugs that have been dispensed in 
Sweden since July, 2005, including dispensation dates and 
active ingredients of the drugs, which are coded according 
to the ATC Classification System. The National Patient 
Register20 includes information on psychiatric inpatient 
care since 1973 and outpatient visits to specialists since 
2001. Each contact with specialty care is recorded and 
includes information on one primary and up to 
eight secondary diagnoses, which are coded according to 
the tenth revision of the International Classification of 
Diseases (ICD-10) from 1997 onwards. Most diagnoses in 
the register have a positive predictive value of about 
85–95%.20 The Total Population Register21 provides 
information on sex, birth, death, and migration for all 
individuals in Sweden.
Outcomes
Psychotic events were defined as any hospital visits 
(inpatient admission or outpatient attendance) because 
of psychosis, according to tvhe recorded ICD-10 codes 
(F1x.5x, F06·0, F06·2, F23, F28, F29, F30·2, F31·2, 
F31·5, F32·3, F33·3, R440, R442, and R443), as recorded 
in the National Patient Register. Chronic psychotic 
conditions were also included (ICD-10 codes F20, F22, 
and F25). We performed all analyses separately in 
patients with and without a history of psychosis.
To investigate the immediate risk of psychotic events 
after initiation of methylphenidate treatment, we compared 
the incidence of these events during the two periods of 
12 weeks on either side of methylphenidate initiation 
(figure 1), designated period 2 (the 12-week period before 
treatment start) and period 3 (the 12-week period after 
treatment start) in those meeting inclusion and exclusion 
criteria. To assess the longer term risk of methylphenidate, 
we compared the incidence of psychotic events during the 
12-week period immediately before methylphenidate 
initiation (period 2) with that during the 12-week period 
one calendar year after methylphenidate initiation 
(designated period 4; ie, approximately 52 weeks to 64 weeks 
after treatment). These represented the primary analyses. 
Figure 1: Study design
Period 1: the same 12 calendar weeks as period 2, 1 year before treatment. Period 2: 12 weeks before treatment 
initiation. Period 3: 12 weeks after treatment initiation. Period 4: the same 12 calendar weeks as period 2, 1 year 
after treatment.
Period 1 Period 2 Period 3 Period 4 
Time
1 year before 
treatment initiation
 1 year after 
treatment initiation
 Initiation of methylphenidate treatment 
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In a secondary analysis, we compared the incidence 
of psychotic events during the 12-week period one 
calendar year after methylphenidate initiation (period 
4) with that during the 12-week period one calendar 
year before methylphenidate initiation (period 1; ie, 
approximately 64 weeks to 52 weeks before treatment; 
figure 1) in those meeting inclusion and exclusion 
criteria. For completeness, we provided results from the 
comparisons between periods 2, 3, and 4 and period 1 
(reference).
As prespecified analyses, we also stratified the main 
analyses by age of incident methylphenidate use 
(adolescent, 12–17 years vs young adult, 18–30 years), to 
investigate how the incidence of psychotic events differed 
by age at treatment initiation. Patients with at least 
one psychotic event before period 1 were considered to 
have had a history of psychosis. Finally, we repeated the 
analyses after excluding patients with chronic psychotic 
conditions, such as schizophrenia (F20.x), persistent 
delusional disorders (F22.x), and schizoaffective disorders 
(F25.x).
Statistical analysis
We used conditional Poisson regression models to 
compare the incidence of psychotic events during a 
potential risk period (period 2, 3, or 4) and the incidence 
during a selected baseline period (period 2 [primary 
analysis] or period 1 [secondary analysis]), with each 
patient as a separate stratum. Only those patients who 
had at least one psychotic event during the selected time 
periods contributed data to the analysis. The results are 
presented as incidence rate ratios (IRRs) and 95% CIs.
In within-individual comparisons, since each patient 
served as his or her own control, all time-constant factors 
that vary between patients (such as genetics and base-
line disease severity) were automatically adjusted for. 
Moreover, seasonal effects were also adjusted for, since 
the 12-week period after treatment was compared with 
equivalent 12-week periods in the previous and sub-
sequent years. To test the robustness of results from a 
12-week period, we also did sensitivity analyses by 
setting the length of each observation period to be 8 and 
24 weeks, instead of 12 weeks. As for the main analyses, 
all time-constant factors were adjusted for by comparing 
the same individual with themselves. No data were 
missing. 
All tests of statistical hypotheses were assessed at a 
two-sided 5% level of significance. Data management was 
done with SAS version 9.4, and R software version 3.4.3 
was used for statistical analyses.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We searched the Swedish Prescribed Drug Register to 
find individuals who had received methylphenidate 
between Jan 1, 2007 and June 30, 2012. We identified 
61 814 individuals who had started treatment with 
methylphenidate. However, we excluded 30 614 (49·5%) 
individuals because they did not meet age criteria, 
400 (0·6%) individuals because they had emigrated, 
immigrated, or died during the study period, and 6902 
(11·2%) individuals because they had received other 
ADHD medications, giving a study population of 
23 898 (38·7%) individuals (appendix p 5). 
The cohort included 9729 (40·7%) women and 
14 169 (59·3%) men (table 1). The median age at 
methylphenidate initiation was 17 years (IQR 14–22). 
A history of psychosis was observed in 479 (2·0%) 
participants. 304 (1·3%) individuals had at least one 
psychotic event during the study period. The overall 
incidence of psychotic events was 5·64 events per 
10 000 person-weeks (95% CI 5·38–5·91); in those with 
a history of psychosis, the incidence was 113·76 events 
per 10 000 person-weeks (105·61–122·53) and, in those 
without a history of psychosis, the incidence was 
3·43 events per 10 000 person-weeks (3·23–3·65).
When we compared the incidence of these events during 
the 12-week periods before and after initiation of methyl-
phenidate treatment (period 3 vs period 2), we found no 
difference in the immediate risk of psychotic events after 
treatment initiation in individuals with a history of 
psychosis (IRR 0·95, 95% CI 0·69–1·30; table 2). Similarly, 
among those without a history of psychosis, we found no 
difference in the immediate risk of psychotic events after 
initiation of methylphenidate treatment (1·04, 0·80–1·34). 
However, relative to the period immediately before 
initiation of methylphenidate treatment (period 2), the IRR 
of psychotic events 1 year later (period 4) was reduced by 
36% in those with a history of psychosis (IRR 0·64, 95% CI 
0·45–0·91; table 2). In those without a history of psychosis, 
the IRR was reduced by 18% (0·82, 0·62–1·07; period 2 vs 
period 4), but this difference was not significant.
See Online for appendix
Characteristics (n=23 898)
Sex, n (%)
Female 9729 (40·7%)
Male 14 169 (59·3%)
Median age at treatment initiation 
(IQR), years
17 (14–22)
Individuals with at least one psychotic event, n (%)
Period 1 89 (0·4%)
Period 2 114 (0·5%)
Period 3 110 (0·5%)
Period 4 94 (0·4%)
Period 1: the 12-week period one calendar year before treatment. Period 2: 
12 weeks before treatment initiation. Period 3: 12 weeks after treatment 
initiation. Period 4: the 12-week period one calendar year after treatment. 
Table 1: Study population characteristics
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The incidence of hospital visits attributed to psychotic 
events during the 64 weeks before and after methyl- 
phenidate medication are shown in figure 2 (for those 
with a history of psychosis) and figure 3 (for those 
without). The incidence of psychotic events appeared to 
be similar before initiation of methylphenidate treatment 
as it was after initiation of treatment (in individuals 
with and those without a history of psychosis). In all 
individuals, the incidence of events decreased during the 
year after initiation of methylphenidate treatment.
In a secondary analysis to compare the incidence of 
events in period 4 (1 year after treatment start) relative to 
period 1 (1 year before treatment start), the IRR of 
psychotic events in those with a history of psychosis was 
reduced by 49% (IRR 0·51, 95% CI 0·36–0·72; table 2). 
In those without a history of psychosis, the IRR of 
psychotic events in period 4 versus period 1 was 
increased by 72% (1·72, 1·23–2·41). However, with 
period 1 as the baseline reference, there was a similar 
risk of psychotic events both immediately before 
(period 2 vs period 1: 2·11, 1·53–2·92) and immediately 
after initiation of methylphenidate treatment (period 3 vs 
period 1: 2·19, 1·58–3·02) in those without a history of 
psychosis.
Participants with at 
least one event
Number of 
events
Person-weeks Incidence per 
10 000 person-weeks (95% CI)
Primary analysis 
IRR (95% CI)
Secondary analysis 
IRR (95% CI)
Individuals with a history of psychosis (n=479)
Period 1 55 (11·5%) 98 5748 170·49 (139·87–207·82) ·· 1 (ref)
Period 2 44 (9·2%) 78 5748 135·70 (108·69–169·42) 1 (ref) 0·80 (0·59–1·07)
Period 3 45 (9·4%) 74 5748 128·74 (102·51–161·68) 0·95 (0·69–1·30) 0·76 (0·56–1·02)
Period 4 30 (6·3%) 50 5748 86·99 (65·93–114·77) 0·64 (0·45–0·91) 0·51 (0·36–0·72)
Individuals without a history of psychosis (n=23 419)
Period 1 34 (0·1%) 54 281 028 1·92 (1·47–2·51) ·· 1 (ref)
Period 2 70 (0·3%) 114 281 028 4·06 (3·38–4·87) 1 (ref) 2·11 (1·53–2·92)
Period 3 65 (0·3%) 118 281 028 4·20 (3·51–5·03) 1·04 (0·80–1·34) 2·19 (1·58–3·02)
Period 4 64 (0·3%) 93 281 028 3·31 (2·70–4·06) 0·82 (0·62–1·07) 1·72 (1·23–2·41)
Data are for the whole cohort (aged 12–30 years at the start of methylphenidate treatment). Period 1: the 12-week period one calendar year before treatment. Period 2: 
12 weeks before treatment initiation. Period 3: 12 weeks after treatment initiation. Period 4: the 12-week period one calendar year after treatment. The primary analysis IRR 
compares periods 2 and 4; the secondary analysis IRR compares all periods with period 1. IRR=incidence rate ratio of psychotic events.
Table 2: Short-term and long-term risk of psychotic events after methylphenidate treatment initiation
Figure 2: Incidence of hospital visits because of psychosis per 10 000 person-weeks, during the 64 weeks before and after methylphenidate treatment 
initiation in individuals with a history of psychosis
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Figure 3: Incidence of hospital visits because of psychosis per 10 000 person-weeks, during the 64 weeks before and after methylphenidate treatment 
initiation in individuals without a history of psychosis
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When stratifying by age group, we found no difference 
in the immediate risk of psychotic events (ie, comparing 
period 3 vs period 2) in adolescents (aged 12–17 years; 
IRR 0·42, 95% CI 0·23–0·79; appendix p 1). We also 
found no difference in the longer term risk of psychosis 
(ie, period 4 vs period 2) in adolescents (0·88, 0·53–1·45). 
There were too few events in adolescents with a history 
of psychosis to draw robust conclusions about the 
differences between those with and those without a 
history of psychosis. We also found no difference in the 
immediate risk of psychotic events (period 3 vs period 2) 
in young adults (age 18–30 years) with a history of 
psychosis (0·96, 0·70–1·32) nor in those without 
(1·27, 0·95–1·69; appendix p 2). Finally, we found no 
difference in the longer term risk of psychosis (period 4 
vs period 2) in young adults with a history of psychosis 
(0·57, 0·39–0·82) nor those without (0·86, 0·62–1·17).
When we excluded participants with chronic psychotic 
conditions (diagnoses F20.x, F22.x or F25.x; n=268) from 
analyses (appendix p 3), we found similar trends to those 
seen in the primary and secondary analyses (table 2). 
When we used the incidences of events during the 
immediate period before initiation of methylphenidate 
treatment (period 2) as the reference values, we found no 
difference in the IRR of psychotic events immediately after 
initiation of methylphenidate treatment when excluding 
those with chronic psychotic diagnoses (IRR 0·98, 95% CI 
0·78–1·24). However, relative to period 2, the IRR of 
psychotic events 1 year after the start of treatment (period 4) 
was reduced by 29% (0·71, 0·55–0·91). Finally, all results 
were similar to those of the primary and secondary 
analyses when the observation period was varied to 8 weeks 
or 24 weeks (appendix p 4).
Discussion
We examined the risk of psychotic events in more than 
23 000 adolescents and young adults after initiation of 
methylphenidate treatment by use of a within-individual 
comparison design. Notably, we found no evidence of an 
increase in the immediate risk of psychotic events when 
comparing the 12-week periods before and after initiation 
of methylphenidate treatment, neither for those with or 
without a history of psychosis. However, 1 year after the 
start of methylphenidate treatment, we observed a 
36% reduction in the incidence of psychotic events in 
those with a history of psychosis and an 18% reduction in 
incidence in those without a history of psychosis 
relative to the period immediately before initiation 
of methylphenidate treatment. This finding challenges 
the widely held view that methylphenidate should be 
avoided or its use restricted in individuals with a history 
of psychosis.6,22
In a secondary analysis of the longer term risks, we 
found no difference in the risk of psychotic events in 
those with a history of psychosis when comparing the 
incidence of events during the 12-week period 1 year after 
methylphenidate initiation with that during the 12-week 
period 1 year before the initiation of methylphenidate. In 
those with no history of psychosis, the incidence of 
psychotic events was greater immediately before and 
after initiation of methylphenidate treatment and 1 year 
after initiation of methylphenidate treatment relative to 
that 1 year before treatment started. 
When we observed the incidence of psychotic events 
over an extended period of 64 weeks before and 64 weeks 
after the initiation of methylphenidate treatment, 
two different trends emerged. First, in those with a history 
of psychosis, the overall incidence of psychotic events 
decreased over time, but the incidence was similar 
immediately before and after initiation of methylphenidate 
treatment. This finding could be explained by a regression 
to the mean, since we would expect that, in any population 
selected for high severity (ie, previous psychotic events), 
there would be a decline in the incidence of these events 
after the initial selection point. Second, in those without a 
history of psychosis, the overall incidence increased over 
time, but the incidence was similar immediately before and 
after initiation of methylphenidate. Given that the proposed 
pharmacological mechanism linking stimulant medication 
and psychotic symptoms predicts an immediate post-
exposure effect rather than a longer term effect, the 
increasing incidence with time could be explained by an 
age effect, with the background incidence of psychotic 
events increasing during a 2-year observation period for 
individuals aged 12–30 years.
We found a similar incidence of psychotic events before 
as after methylphenidate initiation, in agreement with 
Man and colleagues,15 which suggests that methylphenidate 
initiation might be driven by factors related to the 
emergence of psychosis rather than methylphenidate 
triggering psychotic events. Contrary to previous reports6 
and clinical guidelines,22 we found no evidence to suggest 
that the risk of psychosis associated with methylphenidate 
was greater in those with a history of psychosis. With a 
similar within-individual design, Viktorin and colleagues23 
observed an increased risk of mania (which might include 
mania with psychotic symptoms: F30·1 and F31·1) after 
methylphenidate monotherapy in a smaller cohort of 
2307 adults with bipolar disorder and comorbid ADHD. 
Hence, our findings do not exclude the risk that 
methylphenidate might elicit a manic episode with 
psychotic symptoms in bipolar disorder patients who are 
not receiving mood stabilisers.
The strengths of our study include the large number of 
participants and the naturalistic clinical setting, in which 
we used validated clinical diagnoses.20 Unlike previous 
studies,5,15 we investigated the longer term outcome of 
methylphenidate exposure 1 year after treatment initiation. 
Our study includes individuals who, for various reasons, 
would have been excluded from or would not have 
volunteered for a clinical trial and provides a longer 
observation period than most trials. Moreover, the use of a 
within-individual design automatically adjusts for many 
individual-specific factors, including ADHD severity, 
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history of and genetic susceptibility to psychosis, and 
environmental factors, which would not be possible to 
adjust for in a conventional epidemiological approach. 
This design provides an improved strategy for handling 
selection effects and confounding by indication in 
pharmaco-epidemiological studies.
A limitation of our study is that, although the design 
allows for extensive adjustment of otherwise unmeasured 
confounders, it does not adjust for changes that might 
have occurred during the 24-month observation period. 
Given the observational nature of the study, we cannot 
rule out the possibility that unmeasured factors might be 
specific to each group. Hence, the increasing incidence 
of psychotic events over 24 months in participants 
without a history of psychosis might be attributable to an 
age effect on the incidence of psychotic diagnoses rather 
than the effect of methylphenidate treatment. However, 
it could also reflect further unmeasured exposure to 
methylphenidate. It is thus important to confirm the 
findings regarding the immediate risk of psychotic 
events after initiation of methylphenidate in other 
samples and with other study designs.
Further limitations of our study include an absence of 
information on methylphenidate dosage, missed doses, 
and the possibility that milder psychotic events not 
resulting in hospital visits might have been missed. Our 
pharmacovigilance study of methylphenidate was limited 
to psychotic events, and we did not consider other adverse 
effects or therapeutic benefits.17,24 We included the coding 
of drug-induced psychosis to ensure that stimulant-
related psychotic adverse events were recorded. We did 
not select participants because of their ADHD diagnosis, 
although this is the only clinically indicated use 
for methylphenidate. We studied clinically prescribed 
methylphenidate use, and so we cannot generalise our 
findings to non-clinically prescribed use. We cannot 
exclude the possible moderating effect of comorbid 
conditions on the effects of methylphenidate. Additionally, 
we did not study other, less frequently used, ADHD 
medications such as atomoxetine and amphetamines 
(eg, dexamphetamine) and, hence, we cannot generalise 
our findings to these medications, which could carry 
different risk.25 Finally, we focused on psychotic events 
associated with methylphenidate treatment, but we did 
not assess concomitant mediation use, including use of 
antipsychotics. Hence, we cannot determine from our 
study whether the risk of psychotic events associated with 
methylphenidate in individuals with a history of psychosis 
is moderated by antipsychotic medication.
In conclusion, contrary to clinical concerns, our study 
did not detect an increased risk of psychotic events in 
adolescents and young adults after starting methyl- 
phenidate treatment. Notably, this finding also applies to 
individuals with a history of psychosis.
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